CEP162

Across TCGA pan-cancer cohorts, CEP162 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CEP162 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CEP162 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CEP162 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and GBM are the cancer types where CEP162 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.748	0.298	.001	27	view →
UCEC	DFS	Median	All	0.959	0.821	.040	4	view →
GBM	OS	Median	All	0.293	0.497	.025	2	view →
LSCC	OS	Quartile	III,IV	0.898	0.637	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CEP162–PDAC (OS)

Open the PDAC breakdown →